Established in 1942 , Lannett is a US-based pharmaceutical contract manufacturer boasting an extensive portfolio of over 100 product families currently in distribution.
Lannett CDMO offers ‘end to end’ solutions covering the initial stages of formulation development to the final phases of commercial supply. Customers benefit from their expertise in the development of oral solid dosage forms of small molecules including highly potent, poorly soluble, and DEA controlled substances.
Ahead of CPHI Barcelona 2023 we interviewed Grant Brock Vice President of Operations to discuss the services that Lannett CDMO offers.
Lannett has a wide range of customers, says Grant, from “virtual customers looking for a home for their products, to those that have their own operations.”
“The world is always changing, and so are we. We’re always looking for new opportunities.” says Grant.
“Our team has decades of experience, but that doesn’t mean we’re stuck in the past. We make sure we leverage that experience and knowledge, by being forward-thinking and coming up with creative solutions that apply today.”
2024: A year of consolidation?
Reflecting on the industry trends for the year ahead, Grant is expecting there to be continued consolidation both in the generic and contract manufacturing space – driven by companies looking for opportunities to drive their plant utilisation effectively.
“When you’re operating a pharmaceutical plant, you have overhead and infrastructure costs, that that don’t go down. To combat the ever-increasing year over year costs, one way to stay competitive is to utilise the plant effectively and control your costs.”
Meet the Lannett CDMO team at CPHI Barcelona 2023, stand 80E30 (hall 8) and visit their website for more information.
Stay ahead of trends and best practices
